---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-019508"
form_type: "8-K"
ticker: "NXGL"
cik: "0001468929"
company_name: "NEXGEL, INC."
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:38:23.189083+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NEXGEL expands partnership with STADA; gets $1M non-dilutive capital for N.A. launches

## Summary
- Expansion includes digestive enzyme formulas and scar/stretch mark solutions for North America.
- STADA will advance $1 million in non-dilutive capital to support product launches and marketing.
- Partnership builds on existing relationship; targets consumer health market in North America.
- CEO Adam Levy cites shared opportunity and acceleration of go-to-market strategy.

## SEC filing metadata
- accession: 0001641172-25-019508
- form_type: 8-K
- ticker: NXGL
- cik: 0001468929
- company_name: NEXGEL, INC.
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468929/000164117225019508/0001641172-25-019508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468929/000164117225019508/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-019508
- JSON: https://secwatch.observer/filing/0001641172-25-019508.json
- Plain text: https://secwatch.observer/filing/0001641172-25-019508.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.